Recent Research Analysts’ Ratings Updates for IQVIA (IQV)

A number of firms have modified their ratings and price targets on shares of IQVIA (NYSE: IQV) recently:

• 2/7/2026 – IQVIA was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 2/6/2026 – IQVIA had its price target lowered by analysts at UBS Group AG from $280.00 to $240.00. They now have a “buy” rating on the stock.
• 2/6/2026 – IQVIA was given a new $250.00 price target on by analysts at BMO Capital Markets.
• 2/6/2026 – IQVIA had its price target lowered by analysts at Stifel Nicolaus from $273.00 to $220.00. They now have a “buy” rating on the stock.
• 2/6/2026 – IQVIA had its price target lowered by analysts at Barclays PLC from $230.00 to $210.00. They now have an “equal weight” rating on the stock.
• 2/6/2026 – IQVIA had its price target lowered by analysts at JPMorgan Chase & Co. from $255.00 to $225.00. They now have an “overweight” rating on the stock.
• 2/6/2026 – IQVIA had its price target lowered by analysts at Jefferies Financial Group Inc. from $270.00 to $255.00. They now have a “buy” rating on the stock.
• 2/6/2026 – IQVIA had its price target lowered by analysts at Citigroup Inc. from $230.00 to $200.00. They now have a “neutral” rating on the stock.
• 2/5/2026 – IQVIA had its “outperform” rating reaffirmed by analysts at Evercore ISI.
• 2/5/2026 – IQVIA had its “outperform” rating reaffirmed by analysts at Evercore Inc. They now have a $225.00 price target on the stock.
• 1/25/2026 – IQVIA was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 1/22/2026 – IQVIA had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 1/22/2026 – IQVIA had its price target raised by analysts at TD Cowen from $215.00 to $245.00. They now have a “hold” rating on the stock.
• 1/17/2026 – IQVIA was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 1/9/2026 – IQVIA was given a new $266.00 price target on by analysts at Mizuho.
• 1/8/2026 – IQVIA had its price target raised by analysts at UBS Group AG from $250.00 to $280.00. They now have a “buy” rating on the stock.
• 1/8/2026 – IQVIA had its price target raised by analysts at Truist Financial Corporation from $265.00 to $290.00. They now have a “buy” rating on the stock.
• 12/20/2025 – IQVIA was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 12/15/2025 – IQVIA was given a new $230.00 price target on by analysts at Barclays PLC.

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.